title: Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia.
abstract: Exosomes are membrane-bound vesicles found in all biological fluids. AML patients' plasma collected at diagnosis contains elevated exosome levels relative to normal donor (ND) plasma. The molecular profile of AML exosomes changes in the course of therapy and may serve as a measure of disease progression or response to therapy. However, plasma contains a mix of exosomes derived from various cell types. To be able to utilize blast-derived exosomes as biomarkers for AML, we have developed an immunoaffinity-based capture method utilizing magnetic microbeads coated with anti-CD34 antibody (Ab). This Ab is specific for CD34, a unique marker of AML blasts. The capture procedure was developed using CD34+ exosomes derived from Kasumi-1 AML cell culture supernatants. The capture capacity of CD34microbeads was shown to linearly correlate with the input exosomes. A 10 uL aliquot of CD34 microbeads was able to capture all of CD34+ exosomes present in 100-1,000 uL of AML plasma. The levels of immunocaptured CD34+ exosomes correlated with the percentages of CD34+ blasts in the AML patients' peripheral blood. The immunocaptured exosomes had a typical cup-shaped morphology by transmission electron microscopy, and their molecular cargo was similar to that of parental blasts. These exosomes were biologically-active. Upon co-incubation with natural killer (NK) cells, captured blast-derived exosomes down-regulated surface NKG2D expression, while non-captured exosomes reduced expression levels of NKp46. Our data provide a proof-of-principle that blast-derived exosomes can be quantitatively recovered from AML patients' plasma, their molecular profile recapitulates that of autologous blasts and they retain the ability to mediate immune suppression. These data suggest that immunocaptured blast-derived exosomes might be useful in diagnosis and/or prognosis of AML in the future.
authors.affiliation: University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Chang Sook
authors.initials: CS
authors.lastname: Hong
authors.affiliation: University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America; University Hospital, Department of Otolaryngology and Head & Neck Surgery, Basel, Switzerland.
authors.forename: Laurent
authors.initials: L
authors.lastname: Muller
authors.affiliation: University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America; University of Pittsburgh School of Medicine, Division of Hematology-Oncology, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Michael
authors.initials: M
authors.lastname: Boyiadzis
authors.affiliation: University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America; University of Pittsburgh School of Medicine, Departments of Pathology, Immunology and Otolaryngology, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Theresa L
authors.initials: TL
authors.lastname: Whiteside
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism*; D014408:Biomarkers, Tumor; D001792:Blood Platelets / Q000737:chemistry / Q000473:pathology; D002458:Cell Fractionation / Q000379:methods; D055252:Cell-Derived Microparticles / Q000473:pathology; D055354:Exosomes / Q000473:pathology*; D006801:Humans; D007694:Killer Cells, Natural / Q000737:chemistry / Q000378:metabolism / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000473:pathology*; D007962:Leukocytes / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology*; D014407:Tumor Cells, Cultured; D014461:Ultracentrifugation
chemical_list: D018952:Antigens, CD34; D014408:Biomarkers, Tumor
references.citation: Nat Rev Immunol. 2002 Aug;2(8):569-79
references.pmid: 12154376
references.citation: Blood. 1998 Dec 1;92(11):4325-35
references.pmid: 9834239
references.citation: Cancer Immunol Immunother. 2014 Jan;63(1):67-72
references.pmid: 24213679
references.citation: J Exp Med. 2002 May 20;195(10):1303-16
references.pmid: 12021310
references.citation: Haematologica. 2003 May;88(5):497-508
references.pmid: 12745269
references.citation: Biotech Histochem. 2012 Apr;87(3):161-8
references.pmid: 22216980
references.citation: Biochem Soc Trans. 2013 Feb 1;41(1):245-51
references.pmid: 23356291
references.citation: Exp Cell Res. 2004 May 1;295(2):315-29
references.pmid: 15093732
references.citation: J Immunol Methods. 2014 Sep;411:55-65
references.pmid: 24952243
references.citation: Semin Immunopathol. 2011 Sep;33(5):441-54
references.pmid: 21688197
references.citation: Nat Med. 2012 Jun;18(6):883-91
references.pmid: 22635005
references.citation: Semin Cancer Biol. 2012 Aug;22(4):342-9
references.pmid: 22369922
references.citation: Nat Rev Drug Discov. 2013 May;12(5):347-57
references.pmid: 23584393
references.citation: Haematologica. 2012 Jul;97(7):966-74
references.pmid: 22511496
references.citation: Mol Cell Proteomics. 2013 Mar;12(3):587-98
references.pmid: 23230278
references.citation: Cytometry B Clin Cytom. 2005 Mar;64(1):18-27
references.pmid: 15668952
references.citation: PLoS One. 2009;4(4):e5219
references.pmid: 19381331
references.citation: Leuk Lymphoma. 2005 Feb;46(2):247-55
references.pmid: 15621809
references.citation: J Clin Oncol. 2011 Feb 10;29(5):487-94
references.pmid: 21220605
references.citation: Front Immunol. 2014 Apr 10;5:160
references.pmid: 24782865
references.citation: Semin Thromb Hemost. 2012 Feb;38(1):102-13
references.pmid: 22314608
references.citation: Nat Biotechnol. 2007 Nov;25(11):1315-21
references.pmid: 17952057
references.citation: Haematologica. 2011 Sep;96(9):1302-9
references.pmid: 21606166
references.citation: Mol Cell Proteomics. 2010 Feb;9(2):197-208
references.pmid: 19837982
references.citation: Blood. 1991 May 1;77(9):2031-6
references.pmid: 2018839
references.citation: Cancer Res. 2006 Sep 15;66(18):9290-8
references.pmid: 16982774
references.citation: J Immunother Cancer. 2013 Aug 27;1(13):
references.pmid: 24353898